Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Leukemia, Myeloid, Acute 4Solid Tumors 2Polycythemia Vera 2Thrombocythemia, Essential 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Diseases 1Glioblastoma 1Colorectal Neoplasms 1Chromosome 17 deletion 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Irinotecan 7Bevacizumab 7Injections 6Cetuximab 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5Capecitabine 5tocilizumab 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3pazopanib 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × RG7388 × Clear all
NCT03362723 2019-06-19

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumors

NCT02828930 2017-12-18

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Hoffmann-La Roche

Phase 1 Completed
8 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡